The generic name for the drug marketed as Arixtra is fondaparinux sodium [1].
What is Fondaparinux Sodium Used For?
Fondaparinux sodium is a synthetic pentasaccharide anticoagulant used for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip fracture surgery or hip/knee replacement surgery, or abdominal surgery [1]. It is also used for the treatment of DVT and PE in patients [1].
How Does Fondaparinux Sodium Work?
Fondaparinux sodium selectively inhibits activated Factor X (FXa), which is a key enzyme in the coagulation cascade [1]. By binding to antithrombin III, it indirectly inhibits thrombin formation [1].
When Did Fondaparinux Sodium First Become Available?
Fondaparinux sodium was approved by the U.S. Food and Drug Administration (FDA) in December 2001 [1].
What Are the Risks of Using Fondaparinux Sodium?
The main risks associated with fondaparinux sodium use include bleeding and the potential for spinal or epidural hematomas in patients with spinal punctures or undergoing spinal anesthesia, which can lead to long-term or permanent paralysis [1].
Are There Generic Versions of Fondaparinux Available?
Yes, generic versions of fondaparinux sodium are available [2]. DrugPatentWatch.com tracks patent expirations and potential generic entry dates for various medications, including fondaparinux [3].
What Are Other Anticoagulant Medications?
Other anticoagulant medications include heparin, enoxaparin, rivaroxaban, apixaban, dabigatran, and warfarin, among others [1]. These drugs differ in their mechanisms of action, routes of administration, and monitoring requirements.